[Field trial with a new betablocker (Solgol)].
In a field trial with nadolol (Solgol) in 14.870 unselected hypertensives, the blood pressure was lowered to the limit or normal range in 59.5%, in 32.4% the normal range was attained with daily doses of 60-240 mg (once daily). Also on changing over from other antihypertensives and betablockers there was a further lowering of blood pressure. This is more marked diastolically (77% of 4.604 diastolic hypertensive patients) and did not decrease with age, in contrast to other betablockers. Whether this peculiar action of nadolol is based on the increase of renal circulation demonstrated for this preparation or on the other hand on the behavior of the peripheral resistance is discussed. In 87% of the patients doses of d1-2 mg/kg body weight, corresponding to 60-120 mg once daily were sufficient to reduce the blood pressure satisfactorily. The preparation is characterized by a long halflife (20-24 hours) and good tolerance.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol
Feldstudie mit einem neuen Betablocker (Solgol).